Prosecution Insights
Last updated: May 29, 2026

AbbVie Inc.

11 pending office actions • 9 art units • 11 examiners • 0 of 11 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days

Portfolio Summary

11
Total Pending OAs
9
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 11 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

7
Overdue
1
Due this week
3
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 11 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (7)Due ≤ 7 days (1)Due ≤ 30 days (3)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
7
Medium (64%)
0
Easy (0%)
4
Unknown (36%)

Rejection Statute Mix

BucketCases
§103 only4 (36%)
§102 only3 (27%)
No statute on record4 (36%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

10
Life Sciences
91% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
1
Mechanical / Eng
9% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

110 h
Manual time on pending OAs
22 h
Time saved (low, 20%)
38 h
Time saved (mid, 35%)
1.0 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
KIM, YUNSOO 1 65.6% +35.2%
CHEN, PO-CHIH 1 74.7% +13.9%
KIM, STEVEN S 1 38.0% +39.5%
SHIAO, REI TSANG 1 80.0% -34.5%
RZECZYCKI, PHILLIP MATTHEW 1 57.4% +45.0%
NOLAN, JASON MICHAEL 1 65.7% -28.3%
PATEL, SAGAR S 1 76.1% +33.8%
VALLE, ERNESTO 1 60.0% +33.3%
CHENG, KAREN 1 76.3% +28.1%
CANELLA, KAREN A 1 62.6% +32.9%

Interview Candidates (8)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17807292 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF CHENG, KAREN 146d overdue
18330171 MODULATORS OF THE INTEGRATED STRESS PATHWAY PATEL, SAGAR S 44d overdue
17733303 IL-1 Binding Proteins CANELLA, KAREN A 44d overdue
18733551 BROMODOMAIN INHIBITORS CHEN, PO-CHIH 19d overdue
18666929 SYSTEMS AND METHODS FOR GENERATING LONGITUDINAL DATA PROFILES FROM MULTIPLE DATA SOURCES KIM, STEVEN S 15d overdue
19190045 RISANKIZUMAB COMPOSITIONS KIM, YUNSOO 3d overdue
17787828 Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof VALLE, ERNESTO 7d
18476916 METHODS OF TREATING HIDRADENITIS SUPPURATIVA RZECZYCKI, PHILLIP MATTHEW 9d

Top Art Units

Art UnitApps
1623 3
1641 1
1621 1
3698 1
1691 1
1625 1
1626 1
1643 1
1611 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
19190045 RISANKIZUMAB COMPOSITIONS KIM, YUNSOO 1641 §103 Non-Final OA 3d overdue Pending Apr 25, 2025
18733551 BROMODOMAIN INHIBITORS CHEN, PO-CHIH 1621 §103 Non-Final OA 19d overdue Pending Jun 04, 2024
18666929 SYSTEMS AND METHODS FOR GENERATING LONGITUDINAL DATA PROFILES FROM MULTIPLE DATA SOURCES KIM, STEVEN S 3698 §103 Non-Final OA 15d overdue Pending May 17, 2024
18572741 Degrader Compounds and Uses Thereof SHIAO, REI TSANG 1691 Other Non-Final OA 22d Pending Dec 20, 2023
18476916 METHODS OF TREATING HIDRADENITIS SUPPURATIVA RZECZYCKI, PHILLIP MATTHEW 1625 §102 Non-Final OA 9d Pending Sep 28, 2023
18462918 MODULATORS OF THE INTEGRATED STRESS PATHWAY NOLAN, JASON MICHAEL 1623 §103 Final Rejection 118d overdue Pending Sep 07, 2023
18330171 MODULATORS OF THE INTEGRATED STRESS PATHWAY PATEL, SAGAR S 1626 §102 Non-Final OA 44d overdue Pending Jun 06, 2023
17787828 Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof VALLE, ERNESTO 1623 §102 Non-Final OA 7d Pending Jun 21, 2022
17807292 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF CHENG, KAREN 1623 Other Non-Final OA 146d overdue Pending Jun 16, 2022
17733303 IL-1 Binding Proteins CANELLA, KAREN A 1643 Other Final Rejection 44d overdue Pending Apr 29, 2022
17325900 METHODS OF TREATING HEAVY MENSTRUAL BLEEDING RICCI, CRAIG D 1611 Other Non-Final OA 13d Pending May 20, 2021

Managing AbbVie Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month